21/06/2011

The Scientific Foundation of the AECC, called tender for the provision of funding to lines of research pursued by stable and competitive groupus for translational cancer research with a basic-clinical. Each program is endowed with € 1,200,000 for 5 years, enhancing the continuity of research funded and bringing stability to the coordination between groups.The program "Molecular alterations associated with tumor progression in endometrial cancer" presented by the Research Unit in Biomedicine and Translational and Pediatric Oncology at Vall d'Hebron Institut de Recerca (VHIR), with Dr. Jaume Reventós as coordinator, is one of the adjudicated within the category of Stable coordinated groups by the Science Foundation of the AECC. On Thursday September 8 took place at the University of Lleida the presentation of the grant with the institutional presence of the Vice Chancellor of the University of Lleida, Ferran Badia, the president of the AECC de Lleida, Manuel López Morell, president of AECC, Isabel Oriol, responsible for institutional development of VHIR, Carmen Netzel, and the Director of Territorial Health Services of Lleida, Antoni Mateu. The scientific coordinator of the group selected, Dr Jaume Reventós, together with Dr. Xavier Matias-Guiu, researcher and director of the IRB Lleida, explained the project, that will search for the molecular alterations associated with drug resistance in endometrial cancer, which enables the design of new treatments for disease control in women in whom surgery is not curative. In addition to VHIR, also collaborate clinical group leaders of Vall d’Hebron University Hospital, as well as the IRB Lleida and the University Hospital of Santiago de Compostela. Also are included the heads of lab groups at IRB, Hospital Santa Creu i Sant Pau, Hospital de Santiago de Compostela and the MD Anderson Foundation International. "https://www.aecc.es/Comunicacion/Noticias/Paginas/Proyectocancerdeendometrio.aspx" More information